化学免疫疗法
医学
背景(考古学)
肿瘤微环境
肺癌
肿瘤科
前瞻性队列研究
棱镜
癌症研究
内科学
癌症
化疗
免疫疗法
免疫系统
临床试验
肺
病理
全身疗法
肿瘤进展
作者
Liangrui Pan,Chenchen Nie,聂德林,Bin Xie,Qiya Song,Ling Xiao,Qiankun Li,Jiayu Qian,Fanghua Hu,Xiong Peng,Yaning Yang,Zhihong Chen,Xiang Wang,Qide Liang,Yang Liu,Desheng Xiao
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2026-11-19
标识
DOI:10.1158/0008-5472.can-26-1365
摘要
Accurate prediction of treatment response remains challenging in cancer. To facilitate response prediction in non-small cell lung cancer (NSCLC), we developed PRISM, an interpretable multiscale graph-learning framework for estimating treatment-specific objective response from pretreatment H&E whole-slide images. PRISM integrated multiresolution tissue representations with a cell-level tumor microenvironment (TME) hypergraph, thereby treating higher-order microenvironmental organization as a learnable component of treatment-response prediction. Samples from 7,082 patients from four Chinese centers were screened. PRISM was evaluated across treatment specific cohorts receiving targeted therapy (T), EGFR-targeted therapy (T_EGFR), immune checkpoint inhibitor–based therapy (ICI), chemoimmunotherapy (CI), and chemotherapy (C) using patient-level internal cross-validation, independent multicenter external validation, and prospective silent validation. PRISM predicted early objective responses across prespecified systemic therapies in NSCLC. In comparison to 18 established multiple-instance learning and computational pathology baseline models, PRISM remained competitive, with numerical advantages in selected tasks. Multiscale attribution and exploratory H&E-derived TME analyses provided spatial context for model predictions. Overall, PRISM offers a morphology-based framework for estimating early response to prespecified systemic therapies and warrants further prospective multicenter evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI